Workflow
Mountain Crest Acquisition Corp. V(MCAGU) - 2023 Q4 - Annual Report

Financial Performance - For the year ended December 31, 2023, the company reported a net loss of 2,251,116,withoperatingcostsof2,251,116, with operating costs of 2,654,975 and interest income of 510,728[162].Thecompanyhasidentifiedaratioof31510,728 [162]. - The company has identified a ratio of 31% for Public Shares and 69% for non-redeemable shares for the year ended December 31, 2023, in calculating net (loss) income per share [183]. Trust Account and Cash Management - As of December 31, 2023, the trust account held a total of 5,613,395, including 5,325,694fromtheIPOand5,325,694 from the IPO and 287,701 in interest income [137]. - The total amount in the trust account reached 69,000,000aftertheunderwritersfullyexercisedtheiroverallotmentoption,resultinginanadditional69,000,000 after the underwriters fully exercised their over-allotment option, resulting in an additional 9,000,000 [164]. - As of December 31, 2023, the company had withdrawn 129,288ofinterestearnedontheTrustAccounttopaytaxes[168].AsofDecember31,2023,thecompanyhadcashof129,288 of interest earned on the Trust Account to pay taxes [168]. - As of December 31, 2023, the company had cash of 16,089 held outside the Trust Account for general working capital purposes [171]. - Cash used in operating activities for the year ended December 31, 2023, was 470,675,withchangesinoperatingassetsandliabilitiesproviding470,675, with changes in operating assets and liabilities providing 2,291,169 of cash [166]. Business Combination and Compliance - The company extended the time to complete its initial Business Combination from February 16, 2024, to May 16, 2024, by depositing 51,932intoitstrustaccount[175].ThecompanyhasuntilNovember16,2024,toconsummateaBusinessCombination,withapotentialmandatoryliquidationifnotcompletedbythatdate[176].ThecompanyenteredintoanonbindingtermsheetwithCUBEBIOCo.,Ltd.foraproposedbusinesscombinationonMay2,2024[158].ThecompanyreceivedanoticefromNasdaqonDecember13,2023,indicatingnoncompliancewiththe51,932 into its trust account [175]. - The company has until November 16, 2024, to consummate a Business Combination, with a potential mandatory liquidation if not completed by that date [176]. - The company entered into a non-binding term sheet with CUBEBIO Co., Ltd. for a proposed business combination on May 2, 2024 [158]. - The company received a notice from Nasdaq on December 13, 2023, indicating non-compliance with the 35,000,000 market value of listed securities requirement [139]. - The company regained compliance with the Nasdaq MVLS Rule on June 5, 2024, after maintaining a market value of 35,000,000orgreaterfortenconsecutivebusinessdays[141].DebtandFinancialObligationsThecompanyissuedanoninterestbearing,unsecuredpromissorynoteof35,000,000 or greater for ten consecutive business days [141]. Debt and Financial Obligations - The company issued a non-interest bearing, unsecured promissory note of 300,000 to the Sponsor, which can be converted into 75,000 shares of Common Stock upon consummation of a Business Combination [172]. - As of December 31, 2023, there was 52,877outstandingunderapromissorynotewithUHYAdvisors,with52,877 outstanding under a promissory note with UHY Advisors, with 5,587 of interest accrued [173]. - The underwriters are entitled to a deferred fee of 0.30perunit,totaling0.30 per unit, totaling 2,070,000, payable only if the company completes a Business Combination [180]. - The company does not have any long-term debt or off-balance sheet financing arrangements as of December 31, 2023 [178][179]. - The company has no obligations or liabilities considered off-balance sheet arrangements as of December 31, 2023 [178]. Accounting and Regulatory Matters - The company does not believe that any recently issued accounting standards will have a material effect on its financial statements [188]. - The company extended the Combination Period twice in 2024, depositing $51,932 each time into its trust account [152].